Caribou Biosciences Appoints Dara Richardson-Heron, M.D., to its Board of Directors and Ruhi Khan as Chief Business Officer
November 08 2021 - 9:00AM
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage
CRISPR genome-editing biopharmaceutical company, today announced
the appointments of Dara Richardson-Heron, M.D., to its board of
directors and Ruhi Khan as its chief business officer. Dr.
Richardson-Heron has more than 25 years of leadership experience in
the healthcare, corporate, nonprofit, and government sectors. Ms.
Khan brings over 20 years of business development and investment
management experience focused on the biotechnology and
pharmaceutical industries.
“Dara and Ruhi join Caribou at an exciting time
as we advance our four wholly-owned allogeneic cell therapies for
the treatment of hematologic malignancies and solid tumors,
including our lead product candidate, CB-010, which is in an
ongoing Phase 1 study,” said Rachel Haurwitz, Ph.D., Caribou’s
president and chief executive officer. “Leveraging our
differentiated chRDNA genome-editing technology and our proprietary
delivery approach, we have established a pipeline of CAR-T and
CAR-NK therapies progressing through development. As we expand our
leadership at Caribou, we look forward to benefitting from the
wealth of experience of both of these talented industry
professionals as we work collectively on behalf of patients we aim
to serve.”
“I am delighted to serve on Caribou’s Board as
the company drives innovation in an exciting new field of
medicine,” said Dr. Richardson-Heron. “I am excited to be part of
the effort to help Caribou develop potentially transformative,
innovative allogeneic cell therapies and enhance accessibility for
patients.”
“Caribou has significant opportunities ahead
with its proprietary chRDNA platform and its potential for broad
application in the development of new medicines for treating
patients with unmet medical needs,” said Ms. Khan. “I look forward
to working with Rachel and the Caribou team to realize the promise
of chRDNA genome editing and to deliver a new generation of
therapies for patients.”
Dr. Richardson-Heron most recently served as
Pfizer’s chief patient officer where she was responsible for
developing the organization’s global strategy to advance
patient-focused programs. In this role, she worked closely with key
stakeholders to seek patients’ voices and input to help the company
achieve health equity and deliver breakthroughs that change
patients’ lives. Prior to joining Pfizer, Dr. Richardson-Heron
served as the chief engagement officer and scientific executive for
the National Institutes of Health’s (NIH) All of Us Research
Program, a nationwide landmark longitudinal research study of over
one million U.S. volunteers to advance diverse and innovative
health research that may lead to more precise treatment and
prevention strategies. Dr. Richardson-Heron also served as chief
executive officer of the YWCA of the USA and chief executive
officer of the Greater NYC Affiliate of Susan G. Komen for the
Cure. Earlier in her career, she worked with United Cerebral Palsy
Association as assistant executive director/national chief medical
officer and served as executive medical director and special
assistant to the chief executive officer at Consolidated Edison
Company of New York. She is a long-serving member of the board of
the New York Foundation for Senior Citizens. Dr. Richardson-Heron
earned an M.D. from New York University School of Medicine, where
she did her internship and residency in internal medicine, and a
B.A. in biology from Barnard College, where she currently serves as
a trustee.
Ms. Khan most recently was the founder of an
advisory firm that provided business development and finance advice
to life science companies. In this role she had extensive senior
management experience as head of business development for
several oncology-focused companies. Previously, she served as head
and vice president of business development for Acorda Therapeutics,
Inc. Prior to Acorda, she worked in a similar capacity at Lexicon
Pharmaceuticals, Inc. She started her career in venture capital
with Fidelity Biosciences Group (now F-Prime Capital) and MPM
Capital Advisors LLC. Ms. Khan holds an M.B.A. in health care
management from The Wharton School, University of Pennsylvania, and
an A.B. in biology from Harvard College.
About Caribou Biosciences,
Inc.Caribou is a clinical-stage CRISPR genome-editing
biopharmaceutical company dedicated to transforming the lives of
patients with devastating diseases by applying the company’s
proprietary chRDNA technology toward the development of
next-generation, genome-edited allogeneic immune cell therapies.
The company is developing a pipeline of genome-edited,
off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of
both hematologic malignancies and solid tumors. The therapies
target cell surface antigens for which autologous CAR-T cell
therapeutics have previously demonstrated clinical proof-of-concept
as well as additional emerging targets.
For more information about Caribou, visit
www.cariboubio.com and follow the company @CaribouBio.
“Caribou Biosciences” and the Caribou logo are
registered trademarks of Caribou Biosciences, Inc.
Forward-Looking Statements This
press release contains forward-looking statements, within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, without limitation,
statements related to Caribou’s strategy, plans and objectives, and
expectations regarding its clinical and preclinical development
programs. Management believes that these forward-looking statements
are reasonable as and when made. However, such forward-looking
statements are subject to risks and uncertainties, and actual
results may differ materially from any future results expressed or
implied by the forward-looking statements. Risks and uncertainties
include without limitation the risks inherent in drug development
such as those associated with the initiation, cost, timing,
progress and results of current and future research and development
programs, preclinical studies, and clinical trials, as well as
other risk factors described from time to time in Caribou’s filings
with the Securities and Exchange Commission, including its final
prospectus filed on July 23, 2021. In light of the significant
uncertainties in these forward-looking statements, you should not
rely upon forward-looking statements as predictions of future
events. Except as required by law, Caribou undertakes no obligation
to update publicly any forward-looking statements for any
reason.
Caribou Biosciences,
Inc. Contact: |
Amy Figueroa, CFA |
Investor Relations and Corporate
Communications |
afigueroa@cariboubio.com |
|
Investors: |
Elizabeth Wolffe, Ph.D., and
Sylvia Wheeler |
Wheelhouse LSA |
lwolffe@wheelhouselsa.com |
swheeler@wheelhouselsa.com |
|
Media: |
Greg Kelley |
Ogilvy |
gregory.kelley@ogilvy.com |
617-461-4023 |
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jul 2023 to Jul 2024